Form 4: Aclaris Therapeutics CFO Kevin Balthaser Reports Stock Transactions
SEC Form 4
Kevin Balthaser, CFO of Aclaris Therapeutics, reports the vesting and subsequent transactions of restricted stock units.
Summary
- On March 1, 2025, Kevin Balthaser, the CFO of Aclaris Therapeutics, engaged in transactions involving Aclaris Therapeutics, Inc. [ACRS] common stock.
- Balthaser acquired 1,100 shares and 2,375 shares of common stock through the vesting of restricted stock units.
- 727 shares were disposed of to cover tax withholding obligations at a price of $1.99 per share.
- Following these transactions, Balthaser directly owns 92,608 shares of Aclaris Therapeutics common stock and 2,375 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard executive compensation practices; it doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders due to the small number of shares involved.
- The vesting of restricted stock units is part of the executive compensation plan, impacting employee benefits.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | Initial vesting date for some of the restricted stock units. |
| 03/01/2024 | Second vesting date for some of the restricted stock units. |
| 03/01/2025 | Date of the reported transactions: vesting of restricted stock units and disposal of shares for tax obligations. |
| 03/04/2025 | Date of the Form 4 filing. |
Keywords
Aclaris Therapeutics, Kevin Balthaser, ACRS, Form 4, Restricted Stock Units, CFO, Stock Transactions, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.